According to a recent LinkedIn post from Brevel Ltd, the company recently visited a cosmetics customer to work on integrating its Brevel Purallis chlorella ingredient into that customer’s product formulations. The post indicates that Purallis is being tested on an actual production line, suggesting progress toward real-world incorporation into personal care products.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that its chlorella-based ingredient is positioned as rich in antioxidants, vitamins, and amino acids, and is framed as supporting skin hydration, elasticity, and cell regeneration. For investors, this activity may signal early commercial traction in the cosmetics and personal care segment, potentially diversifying revenue prospects if testing leads to recurring supply agreements.
The post also emphasizes the ingredient’s characterization as a clean, plant-based active aligned with perceived consumer demand for natural formulations in skincare. This positioning could help Brevel Ltd strengthen its foothold in the growing microalgae and sustainable beauty markets, although the post does not provide details on contract size, pricing, or timelines that would allow for precise financial impact assessment.
By inviting product developers to initiate contact for potential collaboration, the post suggests an active business development push targeting additional cosmetics partners. If such outreach translates into a broader customer base, Brevel Ltd could enhance scale and manufacturing utilization over time, but investors would need further disclosure on volumes, margins, and regulatory considerations to evaluate long-term profitability implications.

